Drugs / D3S-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07456046 | May 2026 → Jan 2028 expected | — | D3 Bio (Wuxi) Co., Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-08-21 | D3 Bio (Wuxi) Co., Ltd | Regulatory D3 Bio Announces FDA Fast TrackDesignation for D3S-003 for KRAS G12D-Mutated Advanced Non-Small Cell LungCancer d3bio.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-21 | D3 Bio (Wuxi) Co., Ltd | D3 Bio Announces FDA Fast TrackDesignation for D3S-003 for KRAS G12D-Mutated Advanced Non-Small Cell LungCancer d3bio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D3S-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07456046 ↗ |
| Route | Oral | “Oral Tablet” NCT07456046 ↗ |